Odylia |

No posts were found.

Odylia Announces Promotion of Ashley Winslow to President and Chief Scientific Officer
Odylia to Host an Update on the RPGRIP1 Gene Therapy Program and Plans for 2022, Feb 3rd
Odylia Therapeutics Granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for OT-004, an Investigational Gene Therapy for RPGRIP1- associated Retinal Dystrophies